Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07), Zacks reports. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $42.49 on Friday. The stock has a 50 day moving average price of $43.60 and a 200 day moving average price of $49.53. Ultragenyx Pharmaceutical has a 52-week low of $37.02 and a 52-week high of $60.37.

Analyst Ratings Changes

RARE has been the subject of a number of research analyst reports. Piper Sandler raised their target price on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday. Royal Bank of Canada reissued an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. TD Cowen lifted their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Wedbush reissued a “neutral” rating and issued a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.43.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total transaction of $413,650.00. Following the completion of the sale, the chief executive officer now directly owns 2,195,712 shares of the company’s stock, valued at $109,785,600. The trade was a 0.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.